Matt Bernstein

Matt Bernstein

Auto-generated profile, based on publicly available information

Matt Bernstein

Department of Radiology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2008 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
CJClifford R. Jack Jr.
Clifford R. Jack Jr.
MBMatt A. Bernstein
Matt A. Bernstein
NFNick C. Fox
Nick C. Fox
PTPaul Thompson
Paul Thompson
GAGene Alexander
Gene Alexander
MWMichael W. Weiner
Michael W. Weiner
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)‐fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical/psychometric assessments are acquiredat multiple time points. All data will be cross‐linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications thatguided protocol development. A major effort was devoted toevaluating 3D T1‐weighted sequences for morphometric analyses. Several options for this sequence were optimized for the relevant manufacturer platforms and then compared in a reduced‐scale clinical trial. The protocol selected for the ADNI study includes: back‐to‐back 3D magnetization prepared rapid gradient echo (MP‐RAGE) scans; B1‐calibration scans when applicable; and an axial proton density‐T2 dual contrast (i.e., echo) fast spin echo/turbo spin echo (FSE/TSE) for pathology detection. ADNI MRI methods seek to maximize scientific utility while minimizing the burden placed on participants. The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom‐based monitoring of all scanners could be used as a model for other multisite trials. J. Magn. Reson. Imaging 2008.

1 February 1998 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
MBMat A. Bernstein
Mat A. Bernstein
XZXiaohong Joe Zhou
Xiaohong Joe Zhou
JPJason A. Polzin
Jason A. Polzin
KKKevin F. King
Kevin F. King
AGAlexander Ganin
Alexander Ganin
GGGary H. Glover
Gary H. Glover

8 October 2010 in Brain
Verified
Journal Article
Open access
PDF file
CJClifford R. Jack
Clifford R. Jack
HWHeather J. Wiste
Heather J. Wiste
PVPrashanthi Vemuri
Prashanthi Vemuri
SWStephen D. Weigand
Stephen D. Weigand
MSMatthew L. Senjem
Matthew L. Senjem
TIThe Alzheimer'S Disease Neuroimaging Initiative
The Alzheimer'S Disease Neuroimaging Initiative
Biomarkers of brain Aβ amyloid deposition can be measured either by cerebrospinal fluid Aβ42 or Pittsburgh compound B positron emission tomography imaging. Our objective was to evaluate the ability of Aβ load and neurodegenerative atrophy on magnetic resonance imaging to predict shorter time-to-progression from mild cognitive impairment to Alzheimer’s dementia and to characterize the effect of these biomarkers on the risk of progression as they become increasingly abnormal. A total of 218 subjects with mild cognitive impairment were identified from the Alzheimer’s Disease Neuroimaging Initiative. The primary outcome was time-to-progression to Alzheimer’s dementia. Hippocampal volumes were measured and adjusted for intracranial volume. We used a new method of pooling cerebrospinal fluid Aβ42 and Pittsburgh compound B positron emission tomography measures to produce equivalent measures of brain Aβ load from either source and analysed the results using multiple imputation methods. We performed our analyses in two phases. First, we grouped our subjects into those who were ‘amyloid positive’ (n = 165, with the assumption that Alzheimer's pathology is dominant in this group) and those who were ‘amyloid negative’ (n = 53). In the second phase, we included all 218 subjects with mild cognitive impairment to evaluate the biomarkers in a sample that we assumed to contain a full spectrum of expected pathologies. In a Kaplan–Meier analysis, amyloid positive subjects with mild cognitive impairment were much more likely to progress to dementia within 2 years than amyloid negative subjects with mild cognitive impairment (50 versus 19%). Among amyloid positive subjects with mild cognitive impairment only, hippocampal atrophy predicted shorter time-to-progression (P < 0.001) while Aβ load did not (P = 0.44). In contrast, when all 218 subjects with mild cognitive impairment were combined (amyloid positive and negative), hippocampal atrophy and Aβ load predicted shorter time-to-progression with comparable power (hazard ratio for an inter-quartile difference of 2.6 for both); however, the risk profile was linear throughout the range of hippocampal atrophy values but reached a ceiling at higher values of brain Aβ load. Our results are consistent with a model of Alzheimer’s disease in which Aβ deposition initiates the pathological cascade but is not the direct cause of cognitive impairment as evidenced by the fact that Aβ load severity is decoupled from risk of progression at high levels. In contrast, hippocampal atrophy indicates how far along the neurodegenerative path one is, and hence how close to progressing to dementia. Possible explanations for our finding that many subjects with mild cognitive impairment have intermediate levels of Aβ load include: (i) individual subjects may reach an Aβ load plateau at varying absolute levels; (ii) some subjects may be more biologically susceptible to Aβ than others; and (iii) subjects with mild cognitive impairment with intermediate levels of Aβ may represent individuals with Alzheimer’s disease co-existent with other pathologies.

1 July 1991 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
NPNorbert J. Pelc
Norbert J. Pelc
MBMatt A. Bernstein
Matt A. Bernstein
ASAnn Shimakawa
Ann Shimakawa
GGGary H. Glover
Gary H. Glover

1 May 2010 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
CJClifford R. Jack
Clifford R. Jack
MBMatt A. Bernstein
Matt A. Bernstein
BBBret J. Borowski
Bret J. Borowski
JGJeffrey L. Gunter
Jeffrey L. Gunter
NFNick C. Fox
Nick C. Fox
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative

1 January 2015 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
Krishna NayakKrishna Nayak
Krishna Nayak
JNJon-Fredrik Nielsen
Jon-Fredrik Nielsen
MBMatt A. Bernstein
Matt A. Bernstein
MMMichael Markl
Michael Markl
PGPeter D. Gatehouse
Peter D. Gatehouse
SRSubha V. Raman
Subha V. Raman
Cardiovascular magnetic resonance (CMR) phase contrast imaging has undergone a wide range of changes with the development and availability of improved calibration procedures, visualization tools, and analysis methods. This article provides a comprehensive review of the current state-of-the-art in CMR phase contrast imaging methodology, clinical applications including summaries of past clinical performance, and emerging research and clinical applications that utilize today’s latest technology.